Table 2.
Effect of vaccines on IP challenge with WNV in wild type mice
| Vaccination | Challenge Dose WNV PFU | # survived/total | P value | |
|---|---|---|---|---|
| Challenge: Day 60, no boost | ||||
| Mock, no challenge | 0 | 5/5 | ||
| Placebo | 102 | 3/5 | ||
| DNA plasmid | 102 | 5/5 | 0.13 | |
| Inactivated WNV | 102 | 5/5 | 0.13 | |
| Live WNV (survivors) | 102 | 5/5 | 0.13 | |
| Challenge: Day 70, one boost | ||||
| Mock | 102 | 4/5 | ||
| Placebo | 102 | 3/5 | 0.64 | |
| DNA plasmid | 102 | 5/5 | 0.32 | |
| Inactivated WNV | 102 | 5/5 | 0.32 | |
| Live WNV (survivors) | 102 | 5/5 | 0.32 | |
Mice were vaccinated DNA plasmid (10 μg), formalin-inactivated WNV New York (100 μl), or placebo vaccines. Mice were challenge after primary immunization at day 60 or ten days after a boost, at day 70 with 102 PFU of WNV by an IP route and monitored for survival for 28 days. Survival was compared to re-challenge of the subset of animals surviving primary infection with live virulent WNV New York. P values were determined using the log rank test.